Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joel Greenberger
University of Pittsburgh at Pittsburgh, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
University of Pittsburgh
Other : IP rights to UPitt
Dr. Greenberger’s conflict arises due to his interest as an inventor of the intellectual property being evaluated/developed in this animal research, which the University of Pittsburgh patented.
Signature-Directed, Sequential Delivery of Radiation Mitigators
The University of Pittsburgh CMCR will capitalize on its discovery of the critical role of oxidative lipidomics in the total body irradiation response to establish the timing of delivery of multiple small molecule radiation mitigators. Several new mitigators will be sequenced for delivery over 24 - 96 hrs. after total body irradiation, administered by one time applied, but sequentially released topical biodegradable microneedle arrays that deliver each drug at a different mechanism-based time. This program will decrease the toxicity of irradiation and increase the number of survivors in both general and vulnerable populations. Project 1: Signature-Directed Combination Mitigator Therapy Based on GS-Nitroxides Project Leader (PL): Greenberger, J. DESCRIPTION (provided by applicant): Project 1 Mitochondrial targeting of anti-apoptotic GS-nitroxide drugs, including JP4-039, has demonstrated highly effective total body irradiation mitigation. Improved radiation mitigation can be achieved by supplementing other new small molecule radiation mitigators with distinct targets and times of effective action during the 24 - 9 hrs. after TBI. We have discovered 6 new small molecule TBI mitigators with mechanisms of action distinct from GS-nitroxides. Specific Aim 1 tests the hypothesis that plasma and tissue signatures of total body irradiation, and their modulation by JP4-039 delivered at 24 hrs after TBI, can be used to direct the time for administration of each of 6 new small molecule radiation mitigators to provide additive or synergistic mitigation outcomes. The second specific aim tests the hypothesis that administration of GS-nitroxide, JP4-039, at 24 hrs. after TBI, modifies the pharmacokinetics (PK) of the second mitigator drug, requiring further modification of time of sequential delivery. The third specific aim tests the hypothesis that signature directed and PK modified delivery of a sequence of radiation mitigator drugs, will be highly effective and safe in conventional as well as vulnerable populations. All specific aims will utilize a novel topical biodegradable microneedle array delivery system for single application of multi-drug sequentially released drugs using different categories of microneedles each with different drug release characteristics. This translational project will take discovery and delivery of multiple radiation mitigators to the next level.
Filed on July 01, 2016.
Tell us what you know about Joel Greenberger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.